Having discovered that dulaglutide and DA4-JC were the two intranasally administered IRAs best able to access brain areas most vulnerable to AD pathology, we tested if the presence of Aβ pathology affected their brain distribution in the APP/PS1 mouse model of AD. This evidence concerns the gene APP and Alzheimer disease.